Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT Assists the Pharmaceutical Industry on Tracking Pharmaceutical Tubing

Published: Thursday, January 23, 2014
Last Updated: Thursday, January 23, 2014
Bookmark and Share
Company issues its 1 millionth certificate for its FIOLAX® glass tubing.

SCHOTT is supporting the pharmaceutical industry in its efforts to track the tubing used to produce pharmaceutical packaging made of glass. The company issued its 1 millionth certificate for its FIOLAX® glass tubing just recently.

These certificates help to identify the products shipped as tubing that are subsequently processed into pharmaceutical packaging, vials or syringes, for example.

They contain more detailed information on the dimensional quality and the quality of the glass. This enables pharmaceutical companies to track their packaging all the way back to the raw material “glass tubing,” if necessary.

Traceability is currently one of the most pressing issues for the pharmaceutical industry. It is closely related to more stringent requirements for quality and safety in manufacturing, shipping and administering medicines. Packaging is thus an integral part of all safety considerations.

SCHOTT became the first company in the industry to allow for all of the pharmaceutical tubing it manufactures to be identified back in 1999. The certificates are applied to the pallet in a clearly visible position and enable customers to inspect incoming shipments more easily because they contain plenty of detailed information.

One part of the certificate can be detached and stored for documentation purposes and used to perform subsequent tracking & tracing inside the e-commerce portal.

SCHOTT’s certificates can be distinguished from the certificates that its competitors use mainly in terms of their great depth of detail and clarity. Besides a description of the product that includes an exact definition of all of the characteristics of importance to the customer, they also contain highly detailed specifications on tolerances.

“In other words, we offer our customers the highest possible transparency and reliable quality,” concludes Jürgen Achatz, Global Sales Director for Pharmaceutical Tubing at SCHOTT.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!